Ascidian Therapeutics entered collaboration and license agreement with Roche for discovery and development of RNA exon editing therapeutics targeting neurological diseases. $42M initial payment plus up to $1.8B in research, clinical and commercial milestones and royalties. Combines Ascidian's RNA exon editor technology with Roche's CNS delivery capabilities.
Key facts
AnnouncedJun 18, 2024
Deal value$1.8B
Deal typeLicensing/Option
Therapeutic areaNeurological diseases (CNS)
IndicationsNeurological diseases (CNS)
Key assetsRNA exon editing platform targeted at neurological diseases